Evidence & regulatory context
- Mechanism
- ChEMBL compound_search returned 0 hits for 'NBQX'. Preclinical AMPA/kainate receptor antagonist tool compound combined with neural-restricted / glial-restricted precursor cell grafts; no confident ChEMBL entity and no matched clinical product.
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatSpinal cord injuryContusionF344; Sprague-DawleyFemaleIntralesional (NBQX and cells at lesion site)NBQX immediately after injury; cells 9 days post-injury
Model: T8/9 spinal cord contusion injury
Combined NBQX and delayed neural precursor grafts improved micturition function and reduced lesion size more than grafts alone.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.8. Machine-extracted fields require source verification.
